Testing GSK5533524 for neoplasms

Exclusion

• −Has a known hypersensitivity to any component of GSK5533524 or its excipients.
• −Has history of severe allergies, or severe infusion related reactions, or idiosyncrasy to recombinant humanized proteins.
• −Has a history of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, congestive heart failure or clinically significant arrhythmia not controlled by Standard of careStandard of careThe treatment normally given for a condition outside a study.Read more → therapy.
• −Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion.
• −Has untreated brain or central nervous system metastases or metastases that have progressed
• −Has a Grade ≥2 corneal epithelial condition.
• −Has any active renal condition
• −Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screeningScreeningThe checks done before joining, to see whether a study fits.Read more →.
• −Has ongoing adverse reactionAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more →(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baselineBaselineYour starting measurements, taken before treatment begins.Read more → status preceding prior therapy.
• −Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or current ILD/pneumonitis.
• −Has a lung-specific intercurrent clinically significant illness
• −Has FEV1 \<50% predicted
• −Has chronic enteritis or inflammatory bowel disease or any history of clinically significant bleeding of gastrointestinal tract or clinically significant obstruction and/or perforation and/or fistulae of GI tract.
• −Has received immunosuppressive agents or required long-term glucocorticoid therapy within 30 days prior to first dose of study treatment.
• −The use of concomitant medications known to prolong the QT/QTc interval or potentially cause torsades de pointes.
• −Has corrected QT interval by Fridericia formula (QTcF) \>470 msec or QTcF \>480 msec for participants with bundle branch block.
• −Has a left ventricular ejection fraction (LVEF) \< 50%.
• −Has risk factors for prolonged QT/QTc or TdP, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old.
• −Has received any cytotoxic chemotherapy drugs, or other anti-tumor drugs within 28 days prior to the first dose of study drug.
• −Has received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study intervention.